Behavioral pharmacology of olanzapine: A novel antipsychotic drug

Journal of Clinical Psychiatry

Volumn 58, Issue SUPPL. 10, 1997, Pages 37-44

  Moore, Nicholas A ^a   Leander, J David ^a   Benvenga, Mark J ^a   Gleason, Scott D ^a   Shannon, Harlan ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ISOPROPYL 6 METHYLERGOLINE 8 CARBOXYLIC ACID 2 HYDROXY 1 METHYLPROPYL ESTER; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RITANSERIN;

ANIMAL EXPERIMENT; ARTICLE; CATALEPSY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; LIMBIC SYSTEM; MOUSE; NEGATIVE SYNDROME; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; BENZODIAZEPINES; CHEMISTRY, PHARMACEUTICAL; CLOZAPINE; CONDITIONING, OPERANT; DOPAMINE ANTAGONISTS; DRUG DESIGN; HUMANS; MAZE LEARNING; MOTOR ACTIVITY; PHENCYCLIDINE; PIRENZEPINE; RECEPTORS, CHOLINERGIC; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 0030861091     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Moore NA, Calligaro DO, Wong DT, et al. The pharmacology of olanzapine and other new antipsychotic agents. Current Opinion in Investigational Drugs 1993;2:281-293
2. Moore NA, Axton MS. Production of climbing behaviour in mice requires both D1 and D2 receptor activation. Psychopharmacology 1988; 94(2): 263-266
3. Moore NA, Rees G, Sanger G. Differential effects of olanzapine and other antipsychotic agents on stimulant-induced hyperactivity [abstract]. Journal of Psychopharmacology 1994;8(S1):A29
4. Arnt J. Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of d-amphetamine. Eur J Pharmacol 1995;283:55-62
5. Moore NA, Tye NC, Axton MS, et al. The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 1992;262:545-551
6. Ellenbroek BA. Treatment of schizophrenia: a clinical and preclimcal evaluation of neuroleptic drugs. Pharmacol Ther 1993;57:1-78
7. Worms P, Broekkamp CLE, Lloyd K. Behavioural effects of neuroleptics. In: Coyle JT, Enna SJ, eds. Neuroleptics: Neurochemical, Behavioral, and Clinical Perspectives. New York, NY: Raven Press; 1983:93-117
8. Cools AR, Prinssen EPM, Ellenbroek BA. The olfactory tubercle as a site of action of neuroleptics with an atypical profile in the paw test: effect of risperidone, prothiphendyl, ORG 5222, sertindole, olanzapine. Psychopharmacology 1995;119:428-439
9. Scheel-Kruger J. Comparison of typical and atypical neuroleptics in the Morris swim maze [abstract]. Behav Pharmacol 1992;3(S1):18
10. Moore NA, Rees G. The effect of olanzapine and other antipsychotic agents on the acquisition of a watermaze task [abstract]. Presented at the International Meeting on Dopamine Disease States; Oct 18-22, 1995; Almeria, Spain
11. Bakshi VP, Geyer MA. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology 1995;122:198-201
12. Corbett R, Camacho F, Woods AT, et al. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology 1995;120:67-74
13. Benvenga MJ, Leander JD. Olanzapine increases rates of punished responding in pigeons. Psychopharmacology 1995;119:133-138
14. Moore NA, Rees G, Sanger G, et al. Effects of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule. Behav Pharmacol 1994;5:196-202
15. Moore NA, Tye NC, Risius FC, et al. The discriminative stimulus properties of clozapine. Presented at the 14th Congress of the Collegium Internationale Neuro-Psychopharmacologicum [abstract]; June 12-14, 1984; Florence, Italy. Page 816
16. 2A receptors. Br J Pharmacol 1995;114:153P
17. Gleason SD, Shannon HE. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine, and serotonin receptor subtype selective antagonists in mice. Psychopharmacology. In press
18. Arnt J. Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol Toxicol 1982;51(4):321-329
19. Colpaert FC, Slangen JF. Drug Discrimination: Applications in CNS Pharmacology. Amsterdam, The Netherlands: Elsevier Science; 1982
20. Goas J, Boston JE. Discriminative stimulus properties of clozapine and chlorpromazine. Pharmacol Biochem Behav 1978;8:235-241
21. Browne RG, Koe BK. Clozapine and agents with similar behavioural and biochemical properties. In: Colpaiert FC, Slangen JF, eds. Drug Discrimination: Applications in CNS Pharmacology. Amsterdam, The Netherlands: Elsevier Science; 1982:241-254
22. Bruhwyler J, Cheide E, Mercier M. Clozapine: an atypical neuroleptic. Neurosci Biobehav Rev 1990;14:357-363
23. Spealman RD, Katz JL. Some effects of clozapine on punished responding by mice and squirrel monkeys. J Pharmacol Exp Ther 1980;212:435-440
24. Wiley JL, Compton AD, Porter JH. Effects of four antipsychotics on punished responding in rats. Pharmacol Biochem Behav 1993;45:263-267
25. Nanry KP, Pollard GT, Howard JL. Olanzapine moderately increases conflict responding but does not produce a benzodiazepine-like cue in rat. Drug Development and Research 1995;34:317-319
26. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995;52:998-1024
27. Bymaster FP, Rasmussen K, Calligaro DO, et al. In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug. J Clin Psychiatry 1997;58(suppl 10):28-36
28. Beasley CM Jr, Tollefson GD, Tran PV. Safety of olanzapine. J Clin Psychiatry 1997;58(suppl 10):13-17